Free Access
Med Sci (Paris)
Volume 19, Number 1, Janvier 2003
Page(s) 63 - 69
Section M/S Revues
Published online 15 January 2003
  1. Daëron M. Fc receptor biology. Annu Rev Immunol 1997; 15: 203–34. [Google Scholar]
  2. Sutton BJ, Gould HJ. The human IgE network. Nature 1993; 366: 421–8. [Google Scholar]
  3. Kinet JP. The high-affinity IgE receptor (FcεRI): from physiology to pathology. Annu Rev Immunol 1999; 17: 931–72. [Google Scholar]
  4. Kinet JP. Atopic allergy and other hypersensitivities. Curr Opin Immunol 1999; 11: 603–5. [Google Scholar]
  5. Hagan P, Blumenthal D, Dunn AJ, Simpson B, Wilkins HA. Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobium. Nature 1991; 349: 243–5. [Google Scholar]
  6. Gounni AS, Lamkhioued B, Ochiai K, et al. Highaffinity IgE receptor on eosinophils is involved in defence against parasites. Nature 1994; 367: 183–6. [Google Scholar]
  7. Jankovic D, Kullberg MC, Dombrowicz D, et al. FcεRI-deficient mice infected with Schistosoma mansoni mount normal Th2-type responses while displaying enhanced liver pathology. J Immunol 1997; 159: 1868–75. [Google Scholar]
  8. Blank U, Ra C, Miller L, White K, Metzger H, Kinet, JP. Complete structure and expression in transfected cells of high affinity IgE receptor. Nature 1989; 337: 187–9. [Google Scholar]
  9. Garman, SC, Wurzburg BA, Tarchevskaya SS, Kinet JP, Jardetzky TS. Structure of the Fc fragment of human IgE bound to its highaffinity receptor FcεRIa. Nature 2000; 406: 259–66. [Google Scholar]
  10. Lin S, Cicala C, Scharenberg AM, Kinet JP. The FcεRIb subunit functions as an amplifier of FcεRIgmediated cell activation signals. Cell 1996; 85: 985–95. [Google Scholar]
  11. Donnadieu E, Jouvin MH, Kinet JP. A second amplifier function for the allergyassociated FcεRI-b subunit. Immunity 2000; 12: 515–23. [Google Scholar]
  12. Dombrowicz D, Lin S, Flamand V, Brini AT, Koller BH, Kinet JP. Allergyassociated FcRb is a molecular amplifier of IgEand IgG-mediated in vivo responses. Immunity 1998; 8: 517–29. [Google Scholar]
  13. Nissim A, Jouvin MH, Eshhar Z. Mapping of the high affinity Fce receptor binding site to the third constant region domain of IgE. EMBO J 1991; 10: 101–7. [Google Scholar]
  14. Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol 1993; 151: 2623–32. [Google Scholar]
  15. Henry AJ, Cook JP, McDonnell JM, et al. Participation of the Nterminal region of Cε3 in the binding of human IgE to its high-affinity receptor FcεRI. Biochemistry 1997; 36: 15568–78. [Google Scholar]
  16. Hakimi J, Seals C, Kondas JA, Danho W, Kochan J. The a subunit of the human IgE receptor is sufficient for high affinity IgE binding. J Biol Chem 1990; 265: 22079–81. [Google Scholar]
  17. Blank U, Ra CS, Kinet JP. Characterization of truncated a chain products from human, rat, and mouse high affinity receptor for immunoglobulin E. J Biol Chem 1991; 266: 2639–46. [Google Scholar]
  18. Letourneur O, Sechi S, Willette-Brown J, Robertson MW, Kinet JP. Glycosylation of human truncated FcεRI a chain is necessary for efficient folding in the endoplasmic reticulum. J Biol Chem 1995; 270: 8249–56. [Google Scholar]
  19. Cook JP, Henry AJ, McDonnell JM, Owens RJ, Sutton BJ, Gould HJ. Identification of contact residues in the IgE binding site of human FcεRIa. Biochemistry 1997; 36: 15579–88. [Google Scholar]
  20. Garman SC, Kinet JP, Jardetzky TS. Crystal structure of the human high-affinity IgE receptor. Cell 1998; 7: 951–61. [Google Scholar]
  21. Mendoza G, Metzger H. Distribution and valency of receptor for IgE on rodent mast cells and related tumour cells. Nature 1976; 264: 548–50. [Google Scholar]
  22. Sechi S, Roller PP, Willette- Brown J, Kinet JP. A conformational rearrangement upon binding of IgE to its high affinity receptor. J Biol Chem 1996; 271: 19256–63. [Google Scholar]
  23. Wurzburg BA, Garman SC, Jardetzky TS. Structure of the human IgE-Fc Cε3-C e- 4 reveals conformational flexibility in the antibody effector domains. Immunity 2000; 13: 375–85. [Google Scholar]
  24. Maxwell KF, Powell MS, Hulett MD, Barton PA, McKenzie I, Hogarth PM. Crystal structure of the human leukocyte Fc receptor, FcγRIIa. Nat Struct Biol 1999; 6: 437–42. [Google Scholar]
  25. Sondermann P, Huber R, Jacob U. Crystal structure of the soluble form of the human FcγRIIb: a new member of the immunoglobulin superfamily at 1.7 Å resolution. EMBO J 1999; 18: 1095–103. [Google Scholar]
  26. Sondermann P, Huber R, Oosthuizen V, Jacob U. The 3.2-Å crystal structure of the human IgG1 Fc fragment-FcγRIII complex. Nature 2000; 406: 267–73. [Google Scholar]
  27. Radaev S, Motyka S, Fridman WH., Sautes- Fridman C, Sun PD. The structure of a human type III Fcg receptor in complex with Fc. J Biol Chem 2001; 276: 16469–77. [Google Scholar]
  28. Ring J, Kramer U, Schafer T, Behrendt H. Why are allergies increasing? Curr Opin Immunol 2001; 13: 701–8. [Google Scholar]
  29. Shields RL, Whether WR, Zioncheck K, et al. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol 1995; 107: 308–12. [Google Scholar]
  30. Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol 2000; 18: 157–62. [Google Scholar]
  31. Boulet P, Chapman KR, Cote J, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997; 155: 1835–40. [Google Scholar]
  32. Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997; 155: 1828–34. [Google Scholar]
  33. Milgrom H, Fick RB Jr, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb- E25 Study Group. N Engl J Med 1999; 341: 1966–73. [Google Scholar]
  34. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18: 254–61. [Google Scholar]
  35. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108: 184–90. [Google Scholar]
  36. Casale TB, Bernstein IL, Busse WW, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997; 100: 110–21. [Google Scholar]
  37. Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106: 253–9. [Google Scholar]
  38. Fahy JV, Cockcroft DW, Boulet LP, et al. Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am J Respir Crit Care Med 1999; 160: 1023–7. [Google Scholar]
  39. Borkowski TA, Jouvin MH, Lin SY, Kinet JP. Minimal requirements for IgEmediated regulation of surface Fc epsilon RI. J Immunol 2001; 167: 1290–6. [Google Scholar]
  40. Saini SS, MacGlashan DW, Togias A, Adelman DC, Lichtenstein LM, Bochner BS. Down-regulation of human basophil IgE and FcεRI a surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol 1999; 162: 5624–30. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.